Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients

Journal of Psychiatric Research

Volumn 45, Issue 11, 2011, Pages 1439-1444

  Sasayama, Daimei ^a,b   Wakabayashi, Chisato ^a   Hori, Hiroaki ^a   Teraishi, Toshiya ^a   Hattori, Kotaro ^a   Ota, Miho ^a   Ishikawa, Masanori ^c   Arima, Kunimasa ^c   Higuchi, Teruhiko ^c   Amano, Naoji ^b   Kunugi, Hiroshi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Genetic polymorphism; Interleukin 6; Schizophrenia; Soluble interleukin 6 receptor

Indexed keywords

ALANINE; ASPARAGINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-6; RISK FACTORS; SCHIZOPHRENIA;

EID: 80053968265     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.06.003     Document Type: Article

References (37)

1. DSM-IV: diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, American Psychiatric Press, Washington D.C. 4th ed.
2. Practice guidelines for the treatment of patients with schizophrenia 1997, American Psychiatric Association, American Psychiatric Press, Washington D.C.
3. Behrens M.M., Ali S.S., Dugan L.L. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. Journal of Neuroscience 2008, 28:13957-13966.
4. Bonafe M., Olivieri F., Cavallone L., Giovagnetti S., Mayegiani F., Cardelli M., et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. European Journal of Immunology 2001, 31:2357-2361.
5. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation 1998, 102:1369-1376.
6. Galicia J.C., Tai H., Komatsu Y., Shimada Y., Akazawa K., Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Geres and Immunity 2004, 5:513-516.
7. Ganguli R., Yang Z., Shurin G., Chengappa K.N., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research 1994, 51:1-10.
8. Gilmore J.H., Fredrik Jarskog L., Vadlamudi S., Lauder J.M. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004, 29:1221-1229.
9. Inagaki A., Inada T., Fujii Y., Yagi G. Equivalent dose of psychotropics 1999, Seiwa Shoten, Tokyo.
10. Jiang C.Q., Lam T.H., Liu B., Lin J.M., Yue X.J., Jin Y.L., et al. Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity (Silver Spring) 2010, 18:1969-1974.
11. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophrenia Research 2000, 44:165-175.
12. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 2005, 6:312-324.
13. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Research 1998, 32:9-15.
14. Loffler S., Klimke A., Kronenwett R., Kobbe G., Haas R., Fehsel K. Clozapine mobilizes CD34(+) hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. Journal of Clinical Psychopharmacology 2010, 30:591-595.
15. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavia 1994, 89:346-351.
16. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. earch 1995, 29:141-152.
17. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
18. Marx C.E., Jarskog L.F., Lauder J.M., Lieberman J.A., Gilmore J.H. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biological Psychiatry 2001, 50:743-749.
19. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences 2009, 63:257-265.
20. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 1997, 247:308-313.
21. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Research 2008, 160:256-262.
22. Olivieri F., Bonafe M., Cavallone L., Giovagnetti S., Marchegiani F., Cardelli M., et al. The -174C/G locus affects in vitro/in vivo IL-6 production during aging. Experimental Gerontology 2002, 37:309-314.
23. Otsubo T., Tanaka K., Koda R., Shinoda J., Sano N., Tanaka S., et al. Reliability and validity of Japanese version of the mini-international neuropsychiatric interview. Psychiatry and Clinical Neurosciences 2005, 59:517-526.
24. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Journal of Neuroscience 2006, 6:666-671.
25. Paul-Samojedny M., Kowalczyk M., Suchanek R., Owczarek A., Fila-Danilow A., Szczygiel A., Kowalski J. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia - a case-control study. Journal of Molecular Neuroscience 2010, 42:112-119.
26. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
27. Rafiq S., Frayling T.M., Murray A., Hurst A., Stevens K., Weedon M.N., et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. ity 2007, 8:552-559.
28. Reich D., Patterson N., Ramesh V., De Jager P.L., McDonald G.J., Tandon A., et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. American Journal of Human Genetics 2007, 80:716-726.
29. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33. [quiz 34-57].
30. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. Internation Immunopharmacology 2007, 27:10695-10702.
31. Sun S., Wang F., Wei J., Cao L.Y., Qi L.Y., Xiu M.H., et al. Association between interleukin-6 receptor polymorphism and patients with schizophrenia. Schizophrenia Research 2008, 102:346-347.
32. van Kammen D.P., McAllister-Sistilli C.G., Kelley M.E., Gurklis J.A., Yao J.K. Elevated interleukin-6 in schizophrenia. Psychiatry Research 1999, 87:129-136.
33. von Kanel R., Kudielka B.M., Preckel D., Hanebuth D., Fischer J.E. Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behavior and Immunity 2006, 20:40-48.
34. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry and Clinical Neurosciences 2010, 64:217-230.
35. Wobbrock J.O., Findlater L., Gergle D., Higgins J.J. The aligned rank transform for nonparametric factorial analyses using only ANOVA procedures. Proceedings of CHI 2011 conference on human factors in computing systems 2011, vol. 1. 143-146.
36. Xu H.M., Wei J., Hemmings G.P. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. British Journal of Psychiatry 1994, 164:251-253.
37. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Journal of Clinical Psychiatry 2004, 65:940-947.